Skip to main content
OnPoint Now
PoliticsUnited States

McKinsey Settles Opioid Charges for $650 Million Amid Ongoing Crisis

Consulting giant McKinsey's hefty settlement follows scrutiny over its role in the opioid epidemic in the US.

Source: bbc.co.uk2 min read
McKinsey Settles Opioid Charges for $650 Million Amid Ongoing Crisis
Image via bbc.co.uk

In brief

The agreement highlights the consequences faced by corporations involved in promoting opioids, amid a growing crisis of addiction and overdose deaths.

McKinsey & Company, a prominent consulting firm, has agreed to a substantial settlement of $650 million (£515 million) to resolve criminal charges linked to its involvement in the ongoing opioid crisis in the United States. The decision comes in the wake of allegations that McKinsey "knowingly and intentionally" aided pharmaceutical giant Purdue Pharma in misbranding its prescription drugs, which significantly contributed to the widespread misuse of opioids.According to the US Department of Justice, McKinsey had conspired with Purdue Pharma, providing strategic advice to enhance the sales of OxyContin, a powerful painkiller containing oxycodone hydrochloride, in ways that skirted regulatory standards. Prosecutors highlighted McKinsey's role in the pharmaceutical marketing strategies that fueled addiction, stating the company was instrumental in aiding and abetting the misrepresentation of the drug.In response to the allegations, McKinsey issued a statement acknowledging its failure to fully recognize the devastating effects opioids were having on society. The crisis has deep-rooted consequences as drug addiction and overdose fatalities have risen alarmingly over the past three decades, initially exacerbated by the widespread prescription of opioids and later intensified by the influx of synthetic drugs such as fentanyl.As part of the settlement, former senior partner Martin Elling is set to plead guilty to charges of obstruction for allegedly destroying key documents relevant to the case. McKinsey will also operate under a deferred prosecution agreement, which will lapse in five years if the firm adheres to specified reform measures.This settlement adds to McKinsey's earlier agreements, including a nearly $1 billion (£792 million) settlement over similar allegations connected with Purdue Pharma and other opioid manufacturers. Purdue Pharma itself faced severe penalties, pleading guilty in 2020 and agreeing to an $8.3 billion (£6.6 billion) settlement while admitting to facilitating the distribution of drugs without legitimate medical purposes.The opioid crisis has claimed nearly 100,000 lives annually in the United States, although recent data indicates a slight decline in overdose deaths. This evolving scenario underscores the urgent need for robust reform and holds firms accountable in preventing further tragedies associated with opioid misuse.

Topics

More on this story